792PDPhase I, open-label, dose-finding study of GSK2636771, a phosphoinositide 3-kinase (PI3K)β inhibitor, in combination with enzalutamide in male subjects with metastatic castration-resistant prostate cancer (mCRPC)
2017
Keywords:
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
0
References
1
Citations
NaN
KQI